IMV Inc. (IMV.TO)
| Previous Close | 2.0100 |
| Open | 2.0000 |
| Bid | 1.9600 x 0 |
| Ask | 1.9800 x 0 |
| Day's Range | 1.9500 - 2.0000 |
| 52 Week Range | 1.6800 - 5.8600 |
| Volume | 30,970 |
| Avg. Volume | 155,670 |
| Market Cap | 161.821M |
| Beta (5Y Monthly) | 1.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5400 |
| Earnings Date | Nov. 10, 2021 - Nov. 15, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.75 |
- Business Wire
Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., October 07, 2021--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that the immunotherapeutic capabilities of its DPX delivery platform will be featured in two e-poster presentations at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics October 7-10, 2021.
- Business Wire
Potential Response Predictors to IMV’s Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., October 01, 2021--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that a poster describing translational data obtained in the DeCidE clinical study in patients with advanced, recurrent ovarian cancer will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 10-14, 2021 in Washington, D
- Business Wire
IMV’s DPX Delivery Technology to be Showcased in Two e-Posters at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., September 30, 2021--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that two abstracts featuring two DPX-based immunotherapies have been accepted for virtual poster presentation at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics on October 7-10, 2021.
